IMAVALVE
Intelligent materials for in-situ heart Valve tissue engineering
| Coordinatore | TECHNISCHE UNIVERSITEIT EINDHOVEN
Organization address
address: DEN DOLECH 2 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Totale costo | 7˙338˙397 € |
| EC contributo | 5˙652˙133 € |
| Programma | FP7-NMP
Specific Programme "Cooperation": Nanosciences, Nanotechnologies, Materials and new Production Technologies |
| Code Call | FP7-NMP-2013-SME-7 |
| Funding Scheme | CP-TP |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-01-01 - 2017-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
TECHNISCHE UNIVERSITEIT EINDHOVEN
Organization address
address: DEN DOLECH 2 contact info |
NL (EINDHOVEN) | coordinator | 1˙440˙313.00 |
| 2 |
UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
CH (ZURICH) | participant | 1˙451˙404.00 |
| 3 |
JENAVALVE TECHNOLOGY GMBH
Organization address
address: GUERICKESTRASSE 25 contact info |
DE (MUNCHEN BAYERN) | participant | 1˙390˙134.00 |
| 4 |
SUPRAPOLIX BV
Organization address
address: HORSTEN 1 contact info |
NL (EINDHOVEN) | participant | 763˙800.00 |
| 5 |
APPLETREE CI GROUP AG
Organization address
address: RUDOLF DIESEL STRASSE 3 contact info |
CH (WINTERTHUR) | participant | 314˙292.00 |
| 6 |
MEDICUT STENT TECHNOLOGY GMBH
Organization address
address: WILHELM BECKER STRASSE 11A contact info |
DE (PFORZHEIM) | participant | 292˙190.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'In situ tissue engineering using a biodegradable synthetic scaffold that recruits endogenous cells from the bloodstream is emerging as a promising technology to create living heart valves inside the human body having the potential to last a life-time: one valve for life. Compared to classical tissue engineered heart valves this new technology demonstrates off-the-shelf availability at substantially reduced cost. The current proposal aims to further develop the synthetic biomaterials needed for the in situ tissue engineering of heart valves, to process these materials into a functional heart valve scaffold, and to perform all the necessary pre-clinical experiments to enable first-in-man clinical application. A novel approach to the biodegradable scaffold will be developed, that combines a relatively slowly degrading (months) elastomeric material with a fast degrading (weeks) bioactive hydrogel material. These materials will be processed into a fibrous heart valve scaffold by means of electrospinning. The elastomeric material ensure long term functionality of the valve while supporting in-vivo mature tissue formation, while the fast eroding hydrogel material controls the early inflammatory response and creates the necessary void space between the elastomeric fibers. A minimally invasive, transapical, implantation technique will be used for the placement of the heart valve scaffold at the aortic position, following our recent results. For this purpose, tailor-made stents will be developed.'